Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

HighField Biopharma Reports Progression-Free Survival in Glioma Patients

publication date: May 31, 2023

HighField Biopharma, a Hangzhou-based company developing immunoliposomes to treat cancer, has published positive early data from a Phase Ia trial of its lead drug in patients with metastatic cancer. HF1K16 is a drug-encapsulated immune-modulating liposome that contains all-trans retinoic acid. In preliminary data from a trial conducted in China, three patients with refractory glioma reported progression-free survival. The company will start a Phase Ib/II trial of the drug for glioma in China. HighField will present an abstract on the ongoing trial, which enrolled patients with metastatic cancers, at the ASCO meeting this weekend. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital